Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2022 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (201)	10/24/2022 1:29:42 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 267

The analyst who downgraded IMUX dropped his target to $5, the lowest of the three who follow the stock. That's more than 150% higher than today's price.

To: technetium who wrote (201)

10/29/2022 2:26:14 PM

From: technetium

2 Recommendations

Recommended By
BulbaMan
Lance Bredvold

Read Replies (1) | Respond to of 267

Just to remind you, last week was good for the NASDAQ composite (+5%), less so for the Biotech composites (+1%), and on average a significant (-1%) loss for the contest portfolios. This week, the NASDAQ was less exuberant but still in the black (+2.2%), the Biotech Indices hugely better (NASDAQ Biotech +6.8%; S&P Biotech +6.2%), and the contest portfolios did better than the NASDAQ Composite, just, (+2.4% for the median portfolio), lagging far behind the Biotech indices. This week, the big mover listing was PCVX (up +110%), based on a very positive test results for a vaccine (“Might Beat Pfizer” said the headline), and completing a $700 million public offering.

As mentioned the portfolios were generally in the black for the week. In the top ten YTD performance portfolios, all but one were in the black for the week, but only two outpaced the S&P Biotech index. Bulbaman (+7.4% for the week) achieved that with a portfolio where almost all of their choices having a good week. The other, BRENDAN_49, by virtue of being the only holder of PCVX was up a healthy +15%, the number one portfolio for the week. This returned him to the top ten list, after a two week absence, and catapulted him all the way to fourth place. Our first place portfolio, DIEGOSAN, didn’t beat the index, but still enough of a win so that they have returned to a positive (+2.6%) YTD, after six weeks in the red.

		Report Time Ranges
			From	To
		Recent	10/28/2022	10/21/2022
		YTD	12/31/21	10/21/2022
Index Performance
			Symbol	Recent	YTD
			^IXIC	2.24%	-29.04%
			^NBI	6.79%	-12.48%
			^SPSIBI	6.24%	-25.07%
Share Performance
Recent				YTD
Top 5		Bottom 5		Top 5		Bottom 5
PCVX	110.690%	ASLN	-24.509%	CBIO	141.66%	GNCA	-99.50%
RNLX	48.444%	SEDANA.ST	-22.936%	OPTN	117.28%	VLON	-95.40%
ETON	30.918%	INZY	-20.721%	FENC	91.36%	OTIC	-95.25%
VSTM	29.766%	ALVR	-20.447%	PCVX	82.26%	PTE	-95.23%
ATHX	25.871%	GOSS	-16.083%	MYOV	71.61%	PLXP	-92.44%
			Top 10 Portfolio YTD		YTD(Portfolio - SPSIBI)	Rec	Rec(Port. - SPSIBI)
			DIEGOSAN	2.56%	27.62%	3.797%	-2.446%
			TECHNETIUM	-18.49%	6.58%	1.840%	-4.403%
			DEW DILIGENCE	-20.65%	4.41%	0.514%	-5.729%
			BRENDAN_49	-21.39%	3.68%	14.537%	8.294%
			GENEGURU	-22.92%	2.14%	4.388%	-1.855%
			ROCKY9	-23.15%	1.91%	4.015%	-2.228%
			BULBAMAN	-23.46%	1.61%	7.440%	1.197%
			HORSEINALFALFA	-25.25%	-0.18%	1.375%	-4.868%
			A.J. MULLEN	-27.41%	-2.34%	5.108%	-1.135%
			BIOSCIENTISTSA	-29.24%	-4.17%	-0.670%	-6.913%
Average and Median Portfolio Performance
	Avg Recent	Avg YTD	Median Recent		Median YTD
	$1,755	-37.23%	MOPGCW	$1,386	TAMBORELLI	-39.52%
	2.78%	-37.23%	THEHAMMER	2.355%	TAMBORELLI	-39.52%